Biblio
Export 10 results:
Author Title Type [ Year] Filters: Keyword is Amyloidogenic Proteins [Clear All Filters]
“The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings.”, J Alzheimers Dis, vol. 94, no. 1, pp. 217-226, 2023.
, “Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective.”, J Alzheimers Dis, vol. 93, no. 4, pp. 1277-1284, 2023.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
, “A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.”, J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
, “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
, “A Super-Resolved View of the Alzheimer's Disease-Related Amyloidogenic Pathway in Hippocampal Neurons.”, J Alzheimers Dis, vol. 83, no. 2, pp. 833-852, 2021.
, “Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People.”, J Alzheimers Dis, vol. 49, no. 2, pp. 387-98, 2016.
, “Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 271-6, 2016.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
,